Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Iovance Biotherapeutics, Inc.    IOVA

IOVANCE BIOTHERAPEUTICS, INC.

(IOVA)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
01/14/2021 01/15/2021 01/19/2021 01/20/2021 01/21/2021 Date
52.03(c) 51.06(c) 50.93(c) 48.91(c) 47.48 Last
1 230 946 981 905 1 540 223 1 549 963 783 895 Volume
+2.77% -1.86% -0.25% -3.97% -2.92% Change
More quotes
Financials (USD)
Sales 2020 - - -
Net income 2020 -257 M - -
Net cash position 2020 662 M - -
P/E ratio 2020 -26,5x
Yield 2020 -
Sales 2021 1,55 M - -
Net income 2021 -302 M - -
Net cash position 2021 422 M - -
P/E ratio 2021 -23,8x
Yield 2021 -
Capitalization 7 174 M 7 174 M -
EV / Sales 2020 -
EV / Sales 2021 4 367x
Nbr of Employees 148
Free-Float 92,4%
More Financials
Company
Iovance Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of cell therapies as novel cancer immunotherapy products designed to harness the power of a patient’s own immune system to eradicate cancer cells. The Company has developed a shorter manufacturing process for Tumor infiltrating lymphocyte (TIL) therapy known as Generation 2... 
More about the company
Notations Surperformance© of Iovance Biotherapeutics, Inc.
Trading Rating : Investor Rating : -
More Ratings
All news about IOVANCE BIOTHERAPEUTICS, INC.
01/19Iovance Biotherapeutics to Present at Upcoming Healthcare Conferences
GL
01/14IOVANCE BIOTHERAPEUTICS : Oppenheimer Adjusts Iovance Biotherapeutics PT to $57 ..
MT
01/07IOVANCE BIOTHERAPEUTICS, INC. : Other Events, Financial Statements and Exhibits ..
AQ
2020Iovance Biotherapeutics to Present at the 39th Annual J.P. Morgan Healthcare ..
GL
2020IOVANCE BIOTHERAPEUTICS : Barclays Adjusts Price Target for Iovance Biotherapeut..
MT
2020IOVANCE BIOTHERAPEUTICS : HC Wainwright Downgrades Iovance Biotherapeutics to Ne..
MT
2020IOVANCE BIOTHERAPEUTICS, INC. : Change in Directors or Principal Officers, Other..
AQ
2020IOVANCE BIOTHERAPEUTICS : Taps Jean-Marc Bellemin for Finance Chief
MT
2020IOVANCE BIOTHERAPEUTICS : Appoints Jean-Marc Bellemin as Chief Financial Officer
AQ
2020Iovance Biotherapeutics to Present at Upcoming Conferences in December
GL
2020IOVANCE BIOTHERAPEUTICS : Presents Clinical Data in Head and Neck Cancer at Soci..
AQ
2020JMP Securities Adjusts Iovance Biotherapeutics' Price Target to $45 From $38,..
MT
2020IOVANCE BIOTHERAPEUTICS : Corporate Presentation
PU
2020IOVANCE BIOTHERAPEUTICS : Presents Clinical Data in Head and Neck Cancer at Soci..
AQ
2020Iovance Biotherapeutics Presents Clinical Data in Head and Neck Cancer at Soc..
GL
More news
News in other languages on IOVANCE BIOTHERAPEUTICS, INC.
2020EN DIRECT DES MARCHES : Thales, Danone, Peugeot, Europcar, Ingenico, Disney, ..
2020STOCK MARKET PARIS : Rester sur le marché ou le quitter, telle est la question
2020EN DIRECT DES MARCHES : Renault, Peugeot, Casino, Vivendi, Bourbon, Gaumont, ..
2020STOCK MARKET PARIS : L'accord commercial Chine / Etats-Unis se profile
More news
Analyst Recommendations on IOVANCE BIOTHERAPEUTICS, INC.
More recommendations
Chart IOVANCE BIOTHERAPEUTICS, INC.
Duration : Period :
Iovance Biotherapeutics, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends IOVANCE BIOTHERAPEUTICS, INC.
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 12
Average target price 52,00 $
Last Close Price 48,91 $
Spread / Highest target 22,7%
Spread / Average Target 6,32%
Spread / Lowest Target -28,4%
EPS Revisions
Managers and Directors
NameTitle
Maria Fardis President, Chief Executive Officer & Director
Iain David Dukes Chairman
Jean-Marc Bellemin Chief Financial Officer & Treasurer
Friedrich Graf Finckenstein Chief Medical Officer
Merrill A. McPeak Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
IOVANCE BIOTHERAPEUTICS, INC.5.41%7 174
EXACT SCIENCES CORPORATION13.50%23 913
GUARDANT HEALTH, INC.26.74%16 329
INVITAE CORPORATION36.16%10 060
BGI GENOMICS CO., LTD.17.29%9 238
ADAPTIVE BIOTECHNOLOGIES CORPORATION13.07%9 145